NEW YORK, July 01, 2020 (GLOBE NEWSWIRE) — Apple Tree Companions (ATP), a number one life sciences enterprise agency, introduced at the moment the creation of 9 Sq. Therapeutics to find novel therapies for motion problems. Primarily based in San Francisco, 9 Sq. Therapeutics is launching with $50 million in dedicated Collection A funding from ATP. The brand new firm will uncover new small-molecule therapeutics for degenerative motion problems together with Parkinson’s illness and amyotrophic lateral sclerosis (ALS), in addition to non-degenerative problems resembling important tremor and dyskinesias, by integrating computational chemistry, biophysics and computational biology into machine-learning-enabled cell profiling platforms for goal identification, chemical optimization and affected person stratification.
“Efficient remedies for motion problems are urgently wanted. After we noticed a novel alternative to find targets on the intersection of rising scientific and technical disciplines, we created 9 Sq. Therapeutics to speed up options for sufferers,” stated ATP founder and managing companion Seth Harrison, M.D., who will chair the brand new firm’s board. “9 Sq. Therapeutics is the primary in a sequence of thrilling ventures that we anticipate rising from our scientific collaborations within the Bay Space.”
9 Sq. Therapeutics grew from a collaboration between ATP and scientists on the College of California San Francisco (UCSF). The corporate’s founders are:
- Matthew Jacobson, Ph.D., professor and chair of the us Division of Pharmaceutical Sciences, a acknowledged authority in computer-aided drug design and computational structural biology who has based a number of well-known life sciences corporations together with World Blood Therapeutics, Circle Pharma, Relay and Cedilla. Jacobson will serve on the 9 Sq. Therapeutics board.
- Steven Altschuler, Ph.D., and Lani Wu, Ph.D., professors within the Division of Pharmaceutical Chemistry at UCSF, leaders within the fields of single-cell evaluation and quantitative imaging. They mix biology, machine studying and arithmetic to develop extremely scalable platforms for novel organic goal discovery and pathway interrogation. A board-observer place at 9 Sq. Therapeutics might be occupied by both Wu or Altschuler.
- Spiros Liras, Ph.D., an ATP enterprise companion who’s a longtime collaborator with Professors Jacobson, Altschuler and Wu and an adjunct professor in UCSF’s Division of Pharmaceutical Chemistry. Liras, who has a number of many years of expertise main scientific innovation and discovery at biopharmaceutical corporations together with Biogen and Pfizer, will function interim CEO of 9 Sq. Therapeutics and might be a director on the brand new firm’s board.
“We imagine that 9 Sq. Therapeutics might be clearly differentiated from different corporations working in motion problems primarily based on our deep experience in computational chemistry and biology, the machine-learning cell imaging platforms and our expertise in pursuing tough targets with novel approaches,” stated Liras. “We stay up for rising our crew and making essential new discoveries on this underserved space.”
Michael Ehlers, M.D., Ph.D., ATP enterprise companion and chief scientific officer, may also function a director on the 9 Sq. Therapeutics board, bringing intensive expertise in neuroscience drug discovery and growth.
About Apple Tree Companions
ATP is a number one life sciences enterprise capital agency with world presence and attain that’s creating the subsequent technology of transformative biotechnology corporations. ATP brings collectively $2.5 billion in property and accessible funding, one of many sector’s most extremely selective funding methodologies, and a seasoned crew of enterprise companions to create a confirmed hub-and-spoke mannequin. ATP works with the world’s most progressive life scientists and supplies the capital, experience, and operational intelligence to construct new corporations and drive long-term worth. For extra info go to www.appletreepartners.com.